# US 2010/0166777 A1 · Hematopoietic cells that express mosc-1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166777 A1
- Document ID: US20100166777A1
- Status: Published application
- Kind: A1
- Application number: 12/601,474
- Filed: 2008-05-27
- Published: 2010-07-01
- Earliest claimed: 2007-05-28
- Assignees: Istituto Nazionale Di Genetica Molecolare - Ingm
- Inventors: Sergio Abrignani; Mariacristina Crosti; Monica Moro
- Web page: https://patentgrep.com/patent/US20100166777A1

## CPC

- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- A61K 38/1709: {from mammals}
- A61P 35/02: specific for leukemia
- C12N 5/0634: {Cells from the blood or the immune system}
- C12N 5/0645: {Macrophages, e.g. Kuepfer cells in the liver; Monocytes}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to ex-vivo cells belonging to the hematopoietic system, characterized by the presence of MOSC-1 protein on cell surface, methods for isolating them and uses thereof.

## Claims

### Claim 1

Ex-vivo cells belonging to the hematopoietic system, characterized by the presence of MOSC-1 protein on cell surface.

### Claim 2 (depends on 1)

The cells according to claim 1, wherein the cells belonging to the hematopoietic system are HSCs and/or myeloid common progenitors, preferably HSCs.

### Claim 3 (depends on 1)

A method for selecting the cells according to claim 1, said method comprising the following steps:
preparing a sample of cells comprising hematopoietic cells,
assessing the presence of MOSC-1 on the surface of the cells of said sample with a ligand for MOSC-1, and
isolating from the sample the cells on which MOSC-1 is present.

### Claim 4 (depends on 3)

The method according to claim 3, further comprising a step in which HSCs and/or myeloid common progenitors are isolated after preparing the sample comprising hematopoietic cells.

### Claim 5 (depends on 1)

A method for assessing in vitro the effect of a biological sample or of an active substance on the growth and maturation of granulocytary or myelocytary cells, said method comprising the following steps:
assessing the number of cells according to claim expressing MOSC-1 present in a cell sample comprising hematopoietic cells,
contacting a biological sample or an active substance with said cell sample comprising hematopoietic cells,
assessing the number of cells according to claim 1 expressing MOSC-1 after adding said biological sample or said active substance, and
assessing the effect deriving from the addition of said biological sample or said active substance on the growth and/or maturation of granulocytary or myelocytary cells.

### Claim 6 (depends on 1)

A drug containing the cells according to claim 1.

### Claim 7 (depends on 1)

A method of increasing one or more populations of cells belonging to a granulocytary or myelocytary hematopoietic lineage, comprising injecting the cells according to claim 1 into the bone marrow of a human in need thereof.

### Claim 8 (depends on 7)

The method according to claim 7, wherein said one or more populations of cells belonging to a granulocytary or myelocytary hematopoietic lineage are granulocytes, monocytes or karyocytes.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the increase of said one or more populations is part of a treatment or prophylaxis for granulocytopenia, thrombocytopenia, agranulocytosis or neutropenia.

### Claim 10

A specific ligand for MOSC-1 protein.

### Claim 11 (depends on 10)

The ligand according to claim 10, wherein the ligand is an antibody or a lectin against MOSC-1.

### Claim 12 (depends on 11)

The ligand according to claim 11, wherein the ligand is an antibody, or a monoclonal antibody.

### Claim 13 (depends on 10)

The ligand according to claim 10, wherein the ligand is bound to a noxious substance.

### Claim 14 (depends on 10)

A drug containing the ligand according to claim 10.

### Claim 15 (depends on 10)

The ligand according to claim 10 for use as a drug in A method for the prophylaxis or treatment of diseases involving cells expressing MOSC-1 and belonging to the hematopoietic system, comprising administering the ligand of claim 10 to a patient in need thereof.

### Claim 16 (depends on 15)

The ligand method according to claim 15, wherein said diseases are acute myeloid leukemia or chronic myeloid leukemia.